{"id":2783226,"date":"2021-05-17T14:41:46","date_gmt":"2021-05-17T18:41:46","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/?post_type=story&p=2783226"},"modified":"2022-02-02T16:44:12","modified_gmt":"2022-02-02T21:44:12","slug":"podcast-how-to-bridge-diversity-gaps-in-cancer-clinical-trials","status":"publish","type":"story","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/stories\/podcast-how-to-bridge-diversity-gaps-in-cancer-clinical-trials\/","title":{"rendered":"Podcast: How to bridge diversity gaps in cancer clinical trials"},"content":{"rendered":"\n
\n
\n \n \n Patients<\/small>\n <\/a>\n \n \n

\n Podcast: How to bridge diversity gaps in cancer clinical trials\n <\/h1>\n

Luther Clark talks with Lazarex Cancer Foundation's Dana Dornsife and Marya Shegog about increasing access among historically underrepresented communities<\/p>\n <\/div>\n\n

\n

May 17, 2021<\/p>\n

\n

Share this article<\/p>\n

\n \nFacebook icon<\/title><\/svg>\n<\/a><\/p>\n

\n\n\n\n\t.st0{fill:#00857C;}\n\n\nX icon<\/title><\/svg>\n<\/a><\/p>\n

\n \nLinkedin icon<\/title><\/svg>\n<\/a><\/p>\n

\n \nEmail icon<\/title><\/svg>\n<\/a><\/p>\n <\/div>\n <\/div>\n\n
\n
\n
\n \n \n \n \n \"Luther\n <\/picture>\n\n <\/figure>\n \n <\/div>\n <\/div>\n\n
\n
\n
\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n\n\n

Diversity in cancer clinical trials is essential to show if potential treatments are safe and work well for people of all different communities. That\u2019s why it\u2019s crucial to break down barriers and increase participation in cancer clinical trials among historically underrepresented communities.<\/p>\n\n\n\n

In this podcast, Luther Clark, Merck\u2019s deputy chief patient officer, speaks with the Lazarex Cancer Foundation\u2019s founder and CEO, Dana Dornsife, and its health equity and diversity coordinator, Marya Shegog, about the work they\u2019ve been doing \u2014 and the work that still needs to be done \u2014 to foster health equity through cancer clinical trials.<\/p>\n\n\n\n

Listen to the podcast<\/h3>\n\n\n\n